Dendreon To File Provenge BLA In 2006 Based On Survival Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Dendreon plans to submit a BLA for its prostate cancer vaccine Provenge in 2006 following FDA feedback suggesting that existing data is sufficient for filing, the firm says.